A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

NCT06556966 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Alzheimer's Disease Psychosis

Interventions

DRUG: LY03020
DRUG: Placebo

Sponsor

Luye Pharma Group Ltd.